The 2016 revision of the World Health Organization classi cation of lymphoid neoplasms, Blood, vol.127, issue.20, pp.2375-90, 2016. ,
Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies, Int J Biol Markers, vol.2, issue.1, pp.49-53, 1987. ,
Immunotherapy of non-Hodgkin's lymphomas, Hematology Am Soc Hematol Educ Program, pp.221-261, 2001. ,
Radioimmunotherapy of Non-Hodgkin lymphomas, Blood, vol.101, issue.2, pp.391-399, 2003. ,
Introduction to radiobiology of targeted radionuclide therapy, Front Med (Lausanne), vol.2, issue.4, p.12, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01934653
Clinical radioimmunotherapy-the role of radiobiology, Nat Rev Clin Oncol, vol.8, issue.12, pp.720-754, 2011. ,
Radioimmunoconjugates for treating cancer: recent advances and current opportunities, Expert Opin Biol Ther, vol.17, issue.7, pp.813-822, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01635514
Treatment of B cell malignancies with131I Lym-1 monoclonal antibodies, Int J Cancer Suppl, vol.41, issue.S3, pp.96-101, 1988. ,
Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphomanovel and emerging therapies, Cancer Manag Res, vol.5, pp.251-69, 2013. ,
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma, Expert Opin Investig Drugs, vol.24, issue.7, pp.897-912, 2015. ,
Assessment of treatmentrelated myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, Blood, vol.105, issue.12, pp.4576-82, 2005. ,
Ef cacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab, J Clin Oncol, vol.23, issue.4, pp.712-721, 2005. ,
Radioimmunotherapy for rst-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network, Eur J Nucl Med Mol Imaging, vol.41, issue.8, pp.1585-92, 2014. ,
Radioimmunotherapy of lymphoma: an underestimated therapy option, Lancet Haematol, vol.4, issue.1, pp.6-7, 2017. ,
Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network, J Nucl Med, vol.52, issue.9, pp.1354-60, 2011. ,
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy, J Clin Oncol, vol.25, issue.27, pp.4285-92, 2007. ,
Radioimmunotherapy of B-cell nonHodgkin's lymphoma, Front Oncol, vol.3, p.177, 2013. ,
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after rst remission in advanced follicular lymphoma, J Clin Oncol, vol.26, issue.32, pp.5156-64, 2008. ,
90Yttrium-ibritumomab tiuxetan consolidation of rst remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median followup of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial, J Clin Oncol, vol.31, issue.16, pp.1977-83, 2013. ,
Radioimmunotherapy of nonHodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?, J Nucl Med, vol.44, issue.12, pp.2000-2018, 2003. ,
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab, Clin Cancer Res, vol.11, issue.14, pp.5215-5237, 2005. ,
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in nonHodgkin's lymphoma by 18F-uorodeoxyglucose positron emission tomography, Haematologica, vol.93, issue.3, pp.390-397, 2008. ,
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma, J Clin Oncol, vol.28, issue.23, pp.3709-3725, 2010. ,
Consolidation anti-CD22 fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial, Lancet Haematol, vol.4, issue.1, pp.35-45, 2017. ,
Lymrit 37-01: updated results of a phase I/II study of 177Lu-Lilotomab satetraxetan, a novel CD37-targeted antibody-radionuclideconjugate in relapsed NHL patients, Hematol Oncol, vol.35, pp.269-70, 2017. ,
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan signi cantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients, Eur J Nucl Med Mol Imaging, vol.45, issue.7, pp.1233-1274, 2018. ,
Red marrow-absorbed dose for non-Hodgkin lymphoma patients treated with 177Lu-Lilotomab satetraxetan, a novel anti-CD37 antibody-radionuclide conjugate, J Nucl Med, vol.58, issue.1, pp.55-61, 2017. ,
Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-Lilotomab Satetraxetan, J Nucl Med, vol.58, issue.1, pp.48-54, 2017. ,
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extradomain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma, Eur J Nucl Med Mol Imaging, vol.41, issue.5, pp.867-77, 2014. ,
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma, Blood, vol.104, issue.3, pp.642-650, 2004. ,
Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identies a new target for radioimmunotherapy, Oncotarget, vol.9, issue.11, pp.9766-75, 2018. ,
Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters, J Nucl Med, vol.41, issue.12, pp.2089-97, 2000. ,
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1, Proc Natl Acad Sci, vol.104, issue.20, pp.8444-8452, 2007. ,
Abstract 104: preclinical microPET/CT imaging of 89Zr-Df-SGN-35 in mice bearing xenografted CD30 expressing and non-expressing tumors, Cancer Res, vol.74, p.104, 2014. ,
Immuno-PET imaging of CD30-positive lymphoma using 89Zr-desferrioxamine-labeled CD30-speci c AC-10 antibody, J Nucl Med, vol.57, issue.1, pp.96-102, 2016. ,
CD38-bispeci c antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies, Blood, vol.131, issue.6, pp.611-631, 2018. ,
Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody, Cancer Biother Radiopharm, vol.19, issue.1, pp.11-23, 2004. ,
Rationales, evidence, and design considerations for fractionated radioimmunotherapy, Cancer, vol.94, issue.4, pp.1332-1380, 2002. ,
Fractionated 90 Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/ BNLI criteria, J Clin Oncol, vol.32, issue.3, pp.212-220, 2014. ,
Yttrium-ibritumomab-tiuxetan as rst-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial, J Clin Oncol, vol.90, issue.3, pp.308-321, 2013. ,
Synthesis and preclinical evaluation of (177)Lu-CHX-A?-DTPA-rituximab as a radioimmunotherapeutic agent for nonHodgkin's lymphoma, Cancer Biother Radiopharm, vol.30, issue.6, pp.240-246, 2015. ,
New directions in radioimmunotherapy of non-Hodgkin's lymphoma, Clin Lymphoma, vol.5, issue.1, p.4, 2004. ,
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study, Anticancer Res, vol.18, issue.4B, pp.2779-88, 1998. ,
Radiometals as payloads for radioimmunotherapy for lymphoma, Clin Lymphoma, vol.5, issue.1, pp.5-10, 2004. ,
Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies, Eur J Nucl Med Mol Imaging, vol.44, issue.3, pp.517-549, 2016. ,
Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology, J Clin Oncol, vol.30, issue.31, pp.3884-92, 2012. ,
Immuno-PET of cancer: a revival of antibody imaging, J Nucl Med, vol.52, issue.8, pp.1171-1173, 2011. ,
Immuno-PET: a navigator in monoclonal antibody development and applications, Oncologist, vol.12, issue.12, pp.1379-89, 2007. ,
Radiation dosimetry study of [(89)Zr]rituximab tracer for clinical translation of B cell NHL imaging using positron emission tomography, Mol Imaging Biol, vol.17, issue.4, pp.539-586, 2015. ,
Evaluation of next-generation anti-CD20 antibodies labeled with zirconium 89 in human lymphoma xenografts, J Nucl Med, vol.59, issue.8, pp.1219-1243, 2018. ,